Clinical Trial ProgressGenelux announced positive initial data from its investigator-sponsored ongoing P1b/2 study evaluating systemically administered Olvi-Vec + platinum chemotherapy in patients with platinum-relapsed or platinum-refractory small cell lung cancer.
Financial PositionThe company announced an equity financing for $10.5M in gross proceeds, which combined with its cash estimate should provide runway into 2026, through the P2 interim in NSCLC and potentially the top-line P3.
Regulatory MilestonesFDA alignment on adding interim overall survival analysis to the progression-free survival primary endpoint in the ovarian cancer trial could support full approval without the need for additional confirmatory trials.